(Q37585946)

21 August 2017

Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis (English)

1 reference

21 August 2017

0 references

0 references

5

Toshifumi Hibi

1 reference

21 August 2017

12

Mamoru Watanabe

1 reference

21 August 2017

4

Takayuki Matsumoto

1 reference

21 August 2017

2

Satoshi Motoya

1 reference

21 August 2017

3

Hiroyuki Hanai

1 reference

21 August 2017

7

Nael M Mostafa

1 reference

21 August 2017

8

Jingdong Chao

1 reference

21 August 2017

10

Anne Camez

1 reference

21 August 2017

11

Roopal B Thakkar

1 reference

21 August 2017

Yasuo Suzuki

1

1 reference

PMC publication ID

3925299

21 August 2017

Anne M Robinson

series ordinal

6

1 reference

PMC publication ID

3925299

21 August 2017

Vipin Arora

series ordinal

9

1 reference

21 August 2017

24 December 2013

1 reference

Journal of Gastroenterology

21 August 2017

1 reference

21 August 2017

49

1 reference

21 August 2017

2

1 reference

21 August 2017

283-294

1 reference

Creative Commons Attribution-NonCommercial 2.5 Generic

21 August 2017

start time

24 December 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Update on biologic pathways in inflammatory bowel disease and their therapeutic relevance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

The role of TNFalpha in ulcerative colitis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Inflammatory Bowel Disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

25 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Effects of family history on inflammatory bowel disease characteristics in Japanese patients.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Prevalence of ulcerative colitis and Crohn's disease in Japan.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Glucocorticoid use, other associated factors, and the risk of tuberculosis

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3925299

Characteristics of Japanese inflammatory bowel disease susceptibility loci

1 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-013-0922-Y

Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-013-0922-Y

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00535-013-0922-Y

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

21 January 2018

1 reference

12 December 2020

European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease

1 reference

12 December 2020

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

12 December 2020

A new measure of health status for clinical trials in inflammatory bowel disease

1 reference

12 December 2020

10.1007/S00535-013-0922-Y

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/udsbyl6okfep7b4a2fuhubma4i

30 July 2022

release_udsbyl6okfep7b4a2fuhubma4i

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/udsbyl6okfep7b4a2fuhubma4i

30 July 2022

https://api.fatcat.wiki/v0/release/udsbyl6okfep7b4a2fuhubma4i

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/udsbyl6okfep7b4a2fuhubma4i

PubMed publication ID

1 reference

30 July 2022